Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of Baricitinib in Healthy Subjects
NCT02340104Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2015
- Primary completion
- Feb 2015
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of baricitinib in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Primary endpoint: Area Under the Concentration Versus Time Curve From Zero to Infinity at 72 hours. Started Jan 2015; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02340104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02340104.